Introduction
============

Esophageal squamous cell carcinoma (ESCC) is one of histologic subtypes of esophageal cancer, and it occurs at a relatively high frequency in China, with five-year survival rates of 14% in Hong Kong ([@b1-ol-0-0-8464]). However, the molecular mechanism underlying the development of ESCC remains poorly understood.

In recent years, substantial advances have been made in ESCC research. Signal transducer and activator of transcription 3 (STAT3) has been demonstrated to be upregulated by the β-catenin/T cell factor pathway in ESCC ([@b2-ol-0-0-8464]). STAT3β expression is significantly associated with a shorter survival time for patients with ESCC, and it may suppress the oncogenic effects of STAT3α in ESCC cell lines ([@b3-ol-0-0-8464]). Furthermore, xerophilusin B can induce the G~2~/M cell cycle arrest and apoptosis of ESCC cells ([@b4-ol-0-0-8464]). A previous study identified that extracellular matrix protein 1b is downregulated in ESCC compared with normal esophageal tissues, and that it served a potential suppressive function in tumorigenesis and metastasis ([@b1-ol-0-0-8464]). Additionally, plasma matrix metalloproteinase 1 was observed to be highly expressed in ESCC compared with normal esophageal tissues, and it may have contributed to the detection and survival prediction of ESCC ([@b5-ol-0-0-8464]). However, the pathogenesis of ESCC is not yet completely characterized.

In 2010, Lee *et al* ([@b6-ol-0-0-8464]) performed gene expression profiling to investigate target genes for hypoxia-inducible factor (HIF) in the esophageal tumor microenvironment; the study identified a number of HIF target genes, including prostaglandin E synthase, cyclooxygenase 2 and insulin-like growth factor binding protein-3. However, the co-expression networks and functional enrichment analysis of the differentially expressed genes (DEGs) in the ESCC samples were not investigated. In the present study, the microarray dataset of GSE17351 produced by Lee *et al* ([@b6-ol-0-0-8464]) was analyzed to identify DEGs in ESCC samples. Following this, the Weighted Correlation Network Analysis (WGCNA), a systems biology method for identifying the correlation between genes across microarray samples ([@b7-ol-0-0-8464]), was used to analyze co-expression networks for the upregulated DEGs. Subsequently, gene ontology (GO) and pathway enrichment analyses were performed for the DEGs in the two most significant network modules. Additionally, the DEGs were validated using another gene expression dataset, GSE20347 ([@b8-ol-0-0-8464]) from the Gene Expression Omnibus (GEO). These results may contribute to an improved understanding of the etiology of ESCC.

Materials and methods
=====================

### Affymetrix microarray data

The GSE17351 microarray expression profile ([@b6-ol-0-0-8464]), based on the platform of the GPL570 \[HG-U133_Plus_2\] Affymetrix Human Genome U133 Plus 2.0 Array (Affymetrix; Thermo Fisher Scientific, Inc., Waltham, MA, USA), was downloaded from the GEO (<http://www.ncbi.nlm.nih.gov/geo/>) database. The dataset contains 5 tumor esophageal mucosa samples and 5 adjacent normal esophageal mucosa samples from 5 male patients with ESCC, with an age range of 51--76 years. All esophageal tissues were originally obtained through surgery at the Okayama University Hospital, Kitano Hospital and the Hospital of the University of Pennsylvania through the Cooperative Human Tissue Network ([@b6-ol-0-0-8464]).

### Data preprocessing

The expression values of all probes in each sample were reduced to a single value by determining the mean expression value via the aggregate function method ([@b9-ol-0-0-8464]). Missing data were assigned using the k-nearest neighbor method ([@b10-ol-0-0-8464]). Quantile normalization for complete data was performed using the preprocess Core package in Bioconductor ([@b11-ol-0-0-8464]). When numerous probes were mapped to one gene, the mid-value of the data was defined as the expression level of the gene. However, when numerous genes were mapped by one probe, this probe was considered to lack specificity, and was removed from the analysis.

### Identification of DEGs

The Linear Models for Microarray Data package of Bioconductor ([@b12-ol-0-0-8464]) was used to identify genes that were significantly differentially expressed in ESCC samples. The raw P-value was adjusted using the Benjamin and Hochberg method ([@b13-ol-0-0-8464]), and a \|log~2~ fold change (FC)\|\>0.585 and P\<0.05 were selected as the cut-off criteria.

### Construction of co-expression networks and identification of co-expression network modules

The WGCNA package of R ([@b7-ol-0-0-8464]) was used to analyze the co-expression network for DEGs, and the co-expression networks were visualized using Cytoscape (Version 3.2.0) ([@b14-ol-0-0-8464]). The weighting coefficient β was set to 25. The adjacency matrix power method ([@b15-ol-0-0-8464]) was used to transfer matrixes to weighted co-expression networks.

Co-expression network modules were obtained using a hierarchical clustering algorithm ([@b16-ol-0-0-8464]). The number of genes in each module was at least 30. Then, the significant modules were identified using correlation coefficient and network significance methods included in the WGCNA package. Gene significance (GS) measure was defined as a function GS, and a module significance (MS) measure as a mean of the GS in the module. A larger MS value indicated a greater association of a module with ESCC.

### GO and pathway enrichment analyses for DEGs in the significant modules

The WGCNA package was used to obtain significant GO terms for DEGs in the significant modules, and the cluster Profiler package of R ([@b17-ol-0-0-8464]) was used to perform Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis for DEGs in modules. P\<0.05 was selected as the cut-off criterion.

### Data validation of the DEGs

The gene expression dataset GSE20347 ([@b8-ol-0-0-8464]) from GEO was used to validate the expression of the identified DEGs. The dataset included the data from 17 micro-dissected ESCC tumor tissues and 17 matched normal adjacent tissues from patients with ESCC. The data were with the GPL571 \[HG-U133A_2\] Affymetrix Human Genome U133A 2.0 Array platform (Affymetrix; Thermo Fisher Scientific, Inc.).

Data preprocessing and DEG identification were performed with the same methods as for the data in GSE17351. The overlapping upregulated and downregulated DEGs between GSE20347 and GSE17351 were identified and illustrated using an online Venn diagram plotter tool (<https://omics.pnl.gov/software/venn-diagram-plotter>). The overlapping DEGs were considered to be preliminarily validated by the GSE20347 dataset.

Results
=======

### Identification of DEGs

Following data preprocessing, a total of 6,899 genes in 10 samples were excluded. Based on the cut-off criteria, 955 DEGs were identified, including 487 upregulated and 468 downregulated DEGs.

### Analysis of co-expression network modules

A total of 24 co-expression network modules were identified. Of these 24, the modules 'blue4' and 'magenta' were the most significantly associated with ESCC ([Fig. 1](#f1-ol-0-0-8464){ref-type="fig"}).

### Construction of co-expression subnetworks for the blue4 and magenta modules

The top 30 genes with the highest connectivity degree in the modules blue4 and magenta were selected for the construction of co-expression subnetworks. In the co-expression subnetworks of the modules blue4 ([Fig. 2](#f2-ol-0-0-8464){ref-type="fig"}) and magenta ([Fig. 3](#f3-ol-0-0-8464){ref-type="fig"}), there were 435 gene interactions per module.

It was observed that a number of DEGs \[including cysteine rich secretory protein 3 (*CRISP3*), neural EGFL like 2 (*NELL2*), MYB proto-oncogene like 2 (*MYBL2*) and plasminogen activator, urokinase (*PLAU*)\] in the co-expression subnetwork of the module blue4 and a number of DEGs \[including *MAL*, protein phosphatase 1 regulatory subunit 3C (*PPP1R3C*), cytochrome P450 family 3 subfamily A member 5 (*CYP3A5*) and biglycan (*BGN*)\] in the co-expression subnetwork of the module magenta had a particularly high \|log~2~FC\|, indicating that these genes may have a greater extent of association with ESCC.

### Enrichment analyses for the DEGs in the co-expression subnetworks of the modules blue4 and magenta

According to GO enrichment analysis, DEGs in the co-expression subnetwork of the module blue4 were predominantly enriched in GO terms regarding cell division, including 'spindle organization' \[e.g., ubiquitin conjugating enzyme E2 C (*UBE2C*) and SAC3 domain containing 1 (*SAC3D1*)\], 'cell cycle process' \[e.g., *UBE2C*, minichromosome maintenance complex component 6 (*MCM6*) and cell division cycle 20 (*CDC20*)\], 'protein binding' (e.g., *UBE2C, MCM6* and *CDC20*) and 'anaphase-promoting complex' (APC; e.g., *UBE2C* and *CDC20*; [Table I](#tI-ol-0-0-8464){ref-type="table"}). In addition, two KEGG pathways were significantly enriched, including 'cell cycle' (*CDC20* and *MCM6*) and 'ubiquitin mediated proteolysis' (e.g., *UBE2C* and *CDC20*; [Table II](#tII-ol-0-0-8464){ref-type="table"}).

DEGs in the co-expression subnetwork of the magenta module were mainly enriched in GO terms associated with metabolism, including 'energy derivation by oxidation of organic compounds' e.g., adenylate cyclase 3 (*ADCY3*), electron transfer flavoprotein dehydrogenase (*ETFDH*) and glucosidase α, acid (*GAA*), 'primary metabolic process' \[e.g., *CYP3A5*, TEA domain transcription factor 4 (*TEAD4*) and transferrin receptor (*TFRC*)\], and 'intracellular membrane-bounded organelle' (e.g., *TEAD4* and *TFRC*; [Table III](#tIII-ol-0-0-8464){ref-type="table"}). However, no KEGG pathways were significantly enriched in the DEGs of the co-expression subnetwork in the magenta module.

### Validation of DEGs

In total, 308 upregulated genes (e.g., *UBE2C, CDC20, MCM6, TFRC* and *TEAD4*) and 215 downregulated genes (e.g., *PPP1R3C* and *MAL*) were identified as overlapping between the GSE17351 and GSE20347 datasets ([Fig. 4](#f4-ol-0-0-8464){ref-type="fig"}).

Discussion
==========

In the present study, a total of 955 DEGs were identified, including 487 upregulated and 468 downregulated DEGs. According to WGCNA analysis, two significant co-expression network modules, blue4 and magenta, were identified. The GO and KEGG pathway enrichment analyses for the top 30 DEGs with the highest connectivity degrees in the module blue4 revealed that a number of DEGs were associated with the 'cell cycle' and 'ubiquitin mediated proteolysis' KEGG pathways, including *UBE2C, CDC20* and *MCM6*.

*UBE2C* encodes a member of the E2 ubiquitin-conjugating enzyme family, which is involved in protein ubiquitination ([@b18-ol-0-0-8464]). *UBE2C* is associated with cell cycle progression and checkpoint control, as it modulates the degradation of short-lived proteins ([@b19-ol-0-0-8464]). A previous study reported that *UBE2C* expression was elevated in 73% (11 of 15) of esophageal adenocarcinoma samples relative to Barrett\'s metaplasia, and the transfection of *UBE2C* small interfering (si)RNA induced the inhibition of cell proliferation and a distortion in cell cycle distribution ([@b20-ol-0-0-8464]). Furthermore, key roles of *UBE2C* have been demonstrated in other cancer types, including hepatocellular carcinoma ([@b21-ol-0-0-8464]), cervical carcinoma ([@b22-ol-0-0-8464]), non-small cell lung cancer ([@b23-ol-0-0-8464]) and pancreatic ductal adenocarcinoma ([@b24-ol-0-0-8464]). *UBE2C* and *CDC20* were identified as being associated with the term 'anaphase-promoting complex' in the present study. The APC serves a crucial role in modulating cell cycle progression via forming two functionally distinct E3 ubiquitin ligase subcomplexes, APC^Cdc20^ and APC^Cadherin\ 1^ ([@b25-ol-0-0-8464]). The inhibition of CDC20 by siRNA may induce G~2~/M cell cycle arrest and suppress cell growth; CDC20 is negatively regulated by p53 ([@b26-ol-0-0-8464]).

Accumulating evidence has demonstrated that CDC20 serves a notable function in the development and progression of human cancer ([@b27-ol-0-0-8464]). Thus, *UBE2C* and *CDC20* may be associated with ESCC. *MCM6* is essential for the initiation of eukaryotic genome replication. A previous study reported that *MCM6* is potentially associated with the lymph node metastasis of ESCC ([@b28-ol-0-0-8464]), indicating the crucial role of *MCM6* in ESCC. In the network, *UBE2C, CDC20* and *MCM6* were all connected with *CRISP3*, which had a high \|log~2~FC\|. The low expression of *CRISP3* in ESCC compared with normal tissue was identified in a previous study ([@b29-ol-0-0-8464]), consistent with the result of the present study. The DNA copy number loss of *CRISP3* has been demonstrated in oral squamous cell carcinoma. Thus, it may be speculated that *CRISP3* is associated with the carcinogenesis of ESCC. Furthermore, *NELL2* was observed to have a higher \|log~2~FC\| in the co-expression subnetwork of the module blue4 in the present study; it was coexpressed with *UBE2C, CDC20, MCM6* and *CRISP3*. A homolog of *NELL2*, it has been demonstrated that the promoter hypermethylation of *NELL1* is higher in ESCC than in normal esophagus tissues, and that it is associated with poor prognosis in early-stage esophageal adenocarcinoma ([@b30-ol-0-0-8464]). Hence, it may be speculated that *NELL2* may function in the occurrence of ESCC.

In the co-expression subnetwork of the magenta module, the upregulated *TFRC* and *TEAD4*, in addition to the downregulated *PPP1R3C, MAL* and *CYP3A5* were observed to have the highest \|log~2~FC\|. A previous study reported that the elevated expression of *TFRC* was associated with the distant metastasis of ESCC, and patients with positive results for *TFRC* mRNA expression have a notably worse prognosis ([@b31-ol-0-0-8464]). Additionally, *TEAD4* is a member of the transcriptional enhancer factor (TEA) family of transcription factors ([@b32-ol-0-0-8464]). TEAD and its coactivators may co-activate gene transcription, and it is pivotal for physiologically important processes including cell proliferation, cell differentiation and stem cell maintenance ([@b32-ol-0-0-8464]). One coactivator of TEAD, Yes-associated protein, is reported to be overexpressed in primary ESCC tumors ([@b33-ol-0-0-8464]). *PPP1R3C* catalyzes reversible protein phosphorylation, which is important in a range of cellular activities. Downregulated *PPP1R3C* was previously observed to be associated with lymph node metastasis in ESCC ([@b34-ol-0-0-8464]) and was identified as potentially contributing to the development of ESCC ([@b35-ol-0-0-8464]). In the present study, *TFRC, TEAD4* and *PPP1R3C* were enriched in 'primary metabolic processes'. Iron metabolism was identified to be altered in esophageal adenocarcinoma, and the overexpression of *TFRC* was associated with increased iron deposition in esophageal adenocarcinoma ([@b36-ol-0-0-8464]). Thus, *TFRC, TEAD4* and *PPP1R3C* may serve important roles in the development of ESCC.

Downregulated *MAL* in ESCC has been identified in previous studies ([@b37-ol-0-0-8464],[@b38-ol-0-0-8464]), which is consistent with the results of the present study. In esophageal cancer, *MAL* is able to suppress esophageal cancer cell motility, invasion and tumorigenicity and promote apoptosis via the Fas pathway ([@b39-ol-0-0-8464]), indicating a potential role for *MAL* in esophageal cancer. Additionally, genetic polymorphisms of *CYP3A5* in combination with the sulfotransferase family 1A member 1 \*2/\*2 genotype are associated with an increased risk of esophageal cancer ([@b40-ol-0-0-8464]), suggesting a crucial role for *CYP3A5* in esophageal cancer.

In the present study, DEGs were also validated using another ESCC gene expression dataset, GSE20347. A total of 308 upregulated genes and 215 downregulated genes were differentially expressed in the same pattern in GSE20347, including the aforementioned upregulated genes *UBE2C, CDC20, MCM6, TFRC* and *TEAD4*, in addition to the downregulated genes *PPP1R3C* and *MAL*. The validation results further indicate that these genes may serve crucial functions in the progression of ESCC.

However, the present study has a number of limitations. Potential microRNAs and transcription factors targeting the identified DEGs should have been identified, and these predictions should have been validated by experiments. In further studies, investigation of the etiology of ESCC will be performed in depth.

In conclusion, in the present study, 487 upregulated and 468 downregulated DEGs were identified. A number of DEGs (e.g., *UBE2C, CDC20* and *MCM6*) enriched in 'cell cycle' and 'ubiquitin mediated proteolysis', those (e.g., *TFRC* and *TEAD4*) enriched in 'primary metabolic process' and 'intracellular membrane-bounded organelle', and a number of others (e.g., *CRISP3, NELL2, PPP1R3C, MAL* and *CYP3A5*), may be important in the initiation and development of ESCC.
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![Relative strength of the association of co-expressed network modules with esophageal squamous cell carcinoma. The x-axis displays the names of the modules.](ol-15-06-8983-g00){#f1-ol-0-0-8464}

![Interaction network for the co-expression module 'blue4'. The size of the nodes is proportional to the value of the \|log~2~fold change\|; gray nodes represent the downregulated genes and white nodes represent the upregulated genes. The width of the lines is proportional to the co-expression coefficient.](ol-15-06-8983-g01){#f2-ol-0-0-8464}

![Interaction network for the co-expression module 'magenta'. The size of the nodes is proportional to the value of \|log~2~fold change\|; gray nodes represent the downregulated genes and white nodes represent the upregulated genes. The width of lines is proportional to the co-expression coefficient.](ol-15-06-8983-g02){#f3-ol-0-0-8464}

![Venn diagram of the number of overlapping up- and downregulated genes between the datasets GSE17351 and GSE20347. The underlined numbers represent the number of downregulated genes; the numbers without an underline represent the number of upregulated genes.](ol-15-06-8983-g03){#f4-ol-0-0-8464}

###### 

Top 5 most significantly enriched GO terms for the 30 differentially expressed genes with the highest connectivity degree in the module 'blue4' in BP and CC, and all significantly enriched terms in MF.

  Category   ID           Term                               P-value    Count   Genes
  ---------- ------------ ---------------------------------- ---------- ------- -----------------------------------------------------------------------------
  BP         GO:0007051   Spindle organization               0.000091   5       UBE2C, SAC3D1, MYBL2, AURKB, NCOR1
  BP         GO:0051225   Spindle assembly                   0.000131   4       SAC3D1, MYBL2, AURKB, NCOR1
  BP         GO:0022402   Cell cycle process                 0.000602   10      CDKN3, UBE2C, SAC3D1, MCM6, MYBL2, KAT2B, AURKB, NOLC1, NCOR1, CDC20
  BP         GO:0000280   Nuclear division                   0.001058   6       UBE2C, SAC3D1, MYBL2, AURKB, NOLC1, CDC20
  BP         GO:0007067   Mitosis                            0.001058   6       UBE2C, SAC3D1, MYBL2, AURKB, NOLC1, CDC20
  MF         GO:0005515   Protein binding                    0.004683   22      CDKN3, GPNMB, ADRM1, UBE2C, LAMB3, MCM6, NELL2, PLAU, NDRG2, CDC20...
  MF         GO:0005488   Binding                            0.032021   26      GNE, CDKN3, GPNMB, ADRM1, UBE2C, MCM6, NELL2, PLAU, NDRG2, CDC20...
  CC         GO:0005680   Anaphase-promoting complex         0.013075   2       UBE2C, CDC20
  CC         GO:0031974   Membrane-enclosed lumen            0.013075   12      UBE2C, CRAT, CACYBP, HNRNPA2B1, MCM6, NUDT1, CCDC86, KAT2B, AURKB, CDC20...
  CC         GO:0005819   Spindle                            0.013075   4       SAC3D1, AURKB, NCOR1, CDC20
  CC         GO:0000152   Nuclear ubiquitin ligase complex   0.013075   2       UBE2C, CDC20
  CC         GO:0044427   Chromosomal part                   0.018472   5       MYBL2, KAT2B, AURKB, H2AFV, NCOR1

GO, Gene Ontology; BP, biological process; CC, cellular component; MF, molecular function.

###### 

Enriched pathways for differentially expressed genes in the module 'blue4'.

  ID         Description                      P-value       Count   Genes
  ---------- -------------------------------- ------------- ------- --------------
  hsa04110   Cell cycle                       0.022640607   2       CDC20, MCM6
  hsa04120   Ubiquitin mediated proteolysis   0.026418251   2       UBE2C, CDC20

###### 

Top 5 most enriched GO terms for differentially expressed genes in the 'magenta' module in BP and CC.

  Category   ID           Term                                                  P-value    Count   Genes
  ---------- ------------ ----------------------------------------------------- ---------- ------- ------------------------------------------------------------------------------
  BP         GO:0015980   Energy derivation by oxidation of organic compounds   0.018735   5       ADCY3, ETFDH, GAA, ATP5O, PPP1R3C
  BP         GO:0055114   Oxidation-reduction process                           0.018735   6       ADCY3, CYP3A5, ETFDH, GAA, ATP5O, PPP1R3C
  BP         GO:0006091   Generation of precursor metabolites and energy        0.027604   5       ADCY3, ETFDH, GAA, ATP5O, PPP1R3C
  BP         GO:0044238   Primary metabolic process                             0.027604   23      CNPPD1, HSPE1, ATP5O, PPP1R3C, PRSS8, SNAPC3, TEAD4, TFRC, ZNF426, FBXO11...
  BP         GO:0021680   Cerebellar Purkinje cell layer development            0.032836   2       AARS, RORA
  CC         GO:0044429   Mitochondrial part                                    0.022333   6       MTERFD2, ETFDH, GATM, HSPE1, ATP5O, PINK1
  CC         GO:0043231   Intracellular membrane-bounded organelle              0.022333   23      PSMA1, RORA, BGN, PINK1, SNAPC3, TEAD4, TFRC, EZR, ZNF426, FBXO11...
  CC         GO:0043227   Membrane-bounded organelle                            0.022333   23      PSMA1, RORA, BGN, PINK1, SNAPC3, TEAD4, TFRC, EZR, ZNF426, FBXO11...
  CC         GO:0031974   Membrane-enclosed lumen                               0.023484   11      MTERFD2, ETFDH, GATM, HSPE1, PSMA1, RORA, BGN, SNAPC3, TEAD4, FBXO11...
  CC         GO:0044444   Cytoplasmic part                                      0.033213   18      RNF11, HSPE1, MAL, ATP5O, BCAP29, PSMA1, BGN, PINK1, TFRC, EZR...

GO, Gene Ontology; BP, biological process; CC, cellular component.
